Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: BostonView who wrote (7579)	10/29/1998 7:17:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Yes there is a chance. And to your second question I must give the same answer. Difficult to say how much impact MacCamant has anymore. Also three weeks ago biotechs were not hot so what he says now may have an impact while what could have been said under different market conditions may produce a different impact. Did any of the other stocks he mentioned as potential buyout candidates go up as much as XOMA? XOMA is seeking to fill a number of new positions that makes it seem as though it is getting prepared for something. It is possible that not all large buyers wait for FDA approval before building a position. It is possible that buying represents building a pre buyout position. But remember the stock is down from near $8 just a few months ago so I am not sure how much to read into recovering half its' loss. XOMA will be making its' third quarter report next week, but I am not sure how much to expect, plus I doubt XOMA would leak news. (Past lawsuit not for leaking but...) The above is the long answer. The short answer is, I have no idea of what is moving the stock.